Aurora kinase A (AURKA) and never in mitosis gene A-related kinase 6 (NEK6) genes are upregulated in erosive esophagitis and esophageal adenocarcinoma

Experimental and Therapeutic Medicine

Volumn 4, Issue 1, 2012, Pages 33-42

  Kasap, Elmas ^a   Boyacioglu, Seda Örenay ^a   Korkmaz, Mehmet ^a   Yuksel, Elif Saritas ^b   Ünsal, Belkis ^b   Kahraman, Erkan ^a   Özütemiz, Ömer ^c   Yuceyar, Hakan ^a  

^a CELAL BAYAR UNIVERSITY   (Turkey)

^b ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c EGE UNIVERSITY   (Turkey)

Author keywords

Aurora kinase A; Erosive esophagitis; Esophageal adenocarcinoma; Never in mitosis gene A related kinase

Indexed keywords

AURORA A KINASE;

ARTICLE; AURORA A KINASE GENE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ESOPHAGEAL ADENOCARCINOMA; GENE; GENE EXPRESSION REGULATION; GENETIC MARKER; GENETIC PREDISPOSITION; HUMAN; HUMAN TISSUE; NEVER IN MITOSIS GENE A RELATED KINASE 6 GENE; POLYMERASE CHAIN REACTION; REFLUX ESOPHAGITIS; UPREGULATION;

EID: 84865752315     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.561     Document Type: Article

References (44)

1. Ekiz F, Ormeci N, Coban S, et al: Association of methylenetetrahydrofolate reductase C677T-A1298C polymorphisms with risk for esophageal adenocarcinoma, Barrett's esophagus, and reflux esophagitis. Dis Esophagus: Sep 23, 2011 (Epub ahead of print).
2. Yoon HH, Khan M, Shi Q, et al: The prognostic value of clinical and pathologic factors in esophageal adenocarcinoma: a Mayo cohort of 796 patients with extended follow-up after surgical resection. Mayo Clin Proc 85: 1080-1089, 2010.
3. Bor S, Vardar R, Ormeci N, et al: Prevalence patterns of gastric cancers in Turkey: model of a developing country with high occurrence of Helicobacter pylori. J Gastroenterol Hepatol 22: 2242-2245, 2007.
4. Reavis KM, Morris CD, Gopal DV, Hunter JG and Jobe BA: Laryngopharyngeal reflux symptoms better predict the presence of esophageal adenocarcinoma than typical gastroesophageal reflux symptoms. Ann Surg 239: 849-856, 2004.
5. Das A: Tumors of the Esophagus. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Feldman M, Friedman L Friedman S and Brandt JL (eds). Saunders Elsevier, Philadelphia, pp745-773, 2010.
6. Zendehdel N, Biramijamal F, Hossein-Nezhad A, Zendehdel N, Sarie H, Doughaiemoghaddam M and Pourshams A: Role of cytochrome P450 2C19 genetic polymorphisms in the therapeutic efficacy of omeprazole in Iranian patients with erosive reflux esophagitis. Arch Iran Med 13: 406-412, 2010.
7. Bayrakçi B, Kasap E, Kitapçioglu G and Bor S: Low prevalence of erosive esophagitis and Barrett esophagus in a tertiary referral center in Turkey. Turk J Gastroenterol 19: 145-151, 2008.
8. Bor S, Mandiracioglu A, Kitapcioglu G, Caymaz-Bor C and Gilbert RJ: Gastroesophageal reflux in a low-income region in Turkey. Am J Gastroenterol 100: 744-754, 2005.
9. Peng D, Hu TL, Jiang A, Washington MK, Moskaluk CA, Schneider-Stock R and El-Rifai W: Location-specific epigenetic regulation of the metallothionein 3 gene in esophageal adenocarcinomas. PLoS One 6: e22009, 2011.
10. Sharma S, Kelly TK and Jones PA: Epigenetics in cancer. Carcinogenesis 31: 27-36, 2010.
11. Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428, 2002.
12. Jones PA and Baylin SBl: The epigenomics of cancer. Cell 128: 683-692, 2007.
13. Feinberg AP, Ohlsson R and Henikoff S: The epigenetic progenitor origin of human cancer. Nat Rev Genet 7: 21-33, 2006.
14. Yoo CB and Jones PA: Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5: 37-50, 2006.
15. Lundell LR, Dent J, Bennett JR, et al: Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 45: 172-180, 1999.
16. Egger G, Liang G, Aparicio A and Jones PA: Epigenetics in human disease and prospects for epigenetic therapy. Nature 429: 457-463, 2004.
17. Tzao C, Tung HJ, Jin JS, et al: Prognostic significance of global histone modifications in resected squamous cell carcinoma of the esophagus. Mod Pathol 22: 252-260, 2009.
18. Cao X, Xia Y, Yang J, et al: Clinical and biological significance of never in mitosis gene A-related kinase 6 (NEK6) expression in hepatic cell cancer. Pathol Oncol Res 18: 201-207, 2012.
19. Malumbres M and Barbacid M: Cell cycle kinases in cancer. Curr Opin Genet Dev 17: 60-65, 2007.
20. Fu J, Bian M, Jiang Q and Zhang C: Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 5: 1-10, 2007.
21. Moniz L, Dutt P, Haider N and Stambolic V: Nek family of kinases in cell cycle, checkpoint control and cancer. Cell Div 6: 18, 2011.
22. Sen S, Zhou H and White RA: A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines. Oncogene 14: 2195-2200, 1997.
23. Reiter R, Gais P, Jütting U, et al: Aurora kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma. Clin Cancer Res 12: 5136-5141, 2006.
24. Rugge M, Fassan M, Zaninotto G, et al: Aurora kinase A in Barrett's carcinogenesis Hum Pathol 41: 1380-1386, 2010.
25. Lo Iacono M, Monica V, Saviozzi S, Ceppi P, Bracco E, Papotti M and Scagliotti GV: Aurora Kinase A expression is associated with lung cancer histological-subtypes and with tumor de-differentiation. J Transl Med 9: 100, 2011.
26. Sillars-Hardebol AH, Carvalho B, de Wit M, et al: Identification of key genes for carcinogenic pathways associated with colorectal adenoma-to-carcinoma progression. Tumour Biol 31: 89-96, 2010.
27. Dar AA, Zaika A, Piazuelo MB, et al: Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions. Cancer 112: 1688-1698, 2008.
28. El-Rifai W and Powell SM: Molecular and biologic basis of upper gastrointestinal malignancy. Gastric carcinoma. Surg Oncol Clin N Am 11: 273-291, 2002.
29. Shaheen N and Ransohoff DF: Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review. JAMA 287: 1972-1981, 2002.
30. Jee HJ, Kim AJ, Song N, Kim HJ, Kim M, Koh H and Yun J: Nek6 overexpression antagonizes p53-induced senescence in human cancer cells. Cell Cycle 9: 4703-4710, 2010.
31. Yin MJ, Shao L, Voehringer D, Smeal T and Jallal B: The serine/threonine kinase Nek6 is required for cell cycle progression through mitosis. J Biol Chem 278: 52454-52460, 2003.
32. Belham C, Roig J, Caldwell JA, Aoyama Y, Kemp BE, Comb M and Avruch J: A mitotic cascade of NIMA family kinases. Nercc1/Nek9 activates the Nek6 and Nek7 kinases. J Biol Chem 278: 34897-34909, 2003.
33. O'Regan L and Fry AM: The Nek6 and Nek7 protein kinases are required for robust mitotic spindle formation and cytokinesis. Mol Cell Biol 29: 3975-3990, 2009.
34. Nassirpour R, Shao L, Flanagan P, Abrams T, Jallal B, Smeal T and Yin MJ: Nek6 mediates human cancer cell transformation and is a potential cancer therapeutic target. Mol Cancer Res 8: 717-728, 2011.
35. Takeno A, Takemasa I, Doki Y, et al: Integrative approach for differentially overexpressed genes in gastric cancer by combining largescale gene expression profiling and network analysis. Br J Cancer 99: 1307-1315, 2008.
36. Lagergren J: Increased incidence of adenocarcinoma of the esophagus and cardia. Reflux and obesity are strong and independent risk factors according to the SECC study. Lakartidningen J 97: 1950-1953, 2000 (In Swedish).
37. Erichsen R, Robertson D, Farkas DK, Pedersen L, Pohl H, Baron J and Sorensen HT: Erosive reflux disease increases risk for esophageal adenocarcinoma risk, compared with non-erosive reflux. Clin Gastroenterol Hepatol: Jan 12, 2012 (Epub ahead of print).
38. Wu SR, Li CF, Hung LY, Huang AM, Tseng JT, Tsou JH and Wang J: MCCAAT/enhancer-binding protein delta mediates tumor necrosis factor alpha-induced Aurora kinase C transcription and promotes genomic instability. J Biol Chem 286: 28662-28670, 2011.
39. Shakespear MR, Halili MA, Irvine KM, Fairlie DP and Sweet MJ: Histone deacetylases as regulators of inflammation and immunity. Trends Immunol 32: 335-343, 2011.
40. Berger J and Bird A: Role of MBD2 in gene regulation and tumorigenesis. Biochem Soc Trans 33: 1537-1540, 2005.
41. Fujita H, Fujii R, Aratani S, Amano T, Fukamizu A and Nakajima T: Antithetic effects of MBD2a on gene regulation. Mol Cell Biol 23: 2645-2657, 2003.
42. Müller-Tidow C, Kügler K, Diederichs S, et al: Loss of expression of HDAC-recruiting methyl-CpG-binding domain proteins in human cancer. Br J Cancer 85: 1168-1174, 2001.
43. Kanai Y, Ushijima S, Nakanishi Y and Hirohashi S: Reduced mRNA expression of the DNA demethylase, MBD2, in human colorectal and stomach cancers. Biochem Biophys Res Commun 2: 962-966, 1999.
44. Chen ZP, Gu DS, Zhou ZP, et al: Decreased expression of MBD2 and MBD4 gene and genomic-wide hypomethylation in patients with primary immune thrombocytopenia. Hum Immunol 72: 486-491, 2011.